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11. SUMMARY
Background and aims: It has been reported that epithelial cells are involved in the process of in-
flammatory bowel disease (IBD) producing proinflammatory cytokines and chemokines. Glucocor-
ticoids, being the most effective drugs for IBD patients, seem to have influence not only on the in-
filtrated inflammatory cells but also on epithelial cells. It is a clinical observation that about 20 % of
IBD patients are resistant to glucocorticoids and requires alternative treatment.
Since there are only few data regarding influence of glucocorticoids on intestinal epithelial cells, the
aim of this work was to characterize the glucocorticoid receptor signalling pathway in the human
colon carcinoma cell line Caco-2 and rat intestinal cell line IEC-6. The second aim of this study was
to test the hypothesis that IL-1b, a major cytokine in IBD may inhibit glucocorticoid receptor ac-
tion.
Methods: The subcellular distribution of glucocorticoid receptor was studied by Western blot and
immunostaining procedures using antibodies against rat and human GR. Its quantity was deter-
mined by radiobinding assay in both cell lines.
The regulatory (activating and repressing) effects of dexamethasone on gene transcription in pres-
ence or absence of IL-1b were analyzed by reporter gene assay using either glucocorticoid receptor-
(pGRE-SEAP) or nuclear factor kappa B responsive element (pNF-kB-SEAP) carrying constructs.
The effect of IL-1b on receptor translocation was investigated by immunostaining. The repressing
effect on gene transcription was further investigated by RT-PCR for TNFa, a cytokine typically
down-regulated by glucocorticoids.
In Caco-2 GR quantity was increased by the GR overexpression vector pRShGRa.
Results: The subcellular distribution of GR was found to be different in the human and rat cells. In
Caco-2 we observed mostly nuclear staining in both Dex-treated and not treated cells, in IEC-6 the
unliganded form of the receptor was located in the cytoplasm, incubation with Dex resulted its
translocation to the nucleus. IL-1b could repress this process.
The two cell lines were different regarding their receptor amount; we detected significant more spe-
cific binding sites in IEC-6 than in Caco-2.
Dexamethasone induced GR mediated transcriptional activity of the reporter gene in dose-
dependent manner, and this process could be repressed by IL-1b in both cell lines. We detected only
functional inhibition of GR, IL-1b did not change GR quantity apparently.
2The proinflammatory cytokine IL-1b could increase NF-kB mediated transcription in each cell line.
Glucocorticoids could inhibit IL-1b induced NF-kB activation only in IEC-6.
IL-1b increased TNFa-mRNA expression, too. Dex had repressive effect only in case of IEC-6 but
not in Caco-2.
Overexpressing GR using pRShGRa vector, both transactivation and transrepression by Dex could
be restored in Caco-2. Blocking the NF-kB-pathway by a dominant negative IkB vector could not
restore glucocorticoid receptor action disturbed by IL-1b.
Conclusions: Our data suggest that proinflammatory cytokines may influence the effect of corti-
costeroids in intestinal epithelial cells.
The quantity of glucocorticoid receptor is crucial for responsiveness. The receptor number under a
certain threshold may render cells unresponsive with respect to transrepressive effects, while trans-
activation is intact.
IL-1b inhibits GR signalling. This inhibition seems to be independent on NF-kB activation since
blocking the NF-kB pathway by IkB overexpression does not counteract the IL-1b effects on glu-
cocorticoid receptor action.
32. INTRODUCTION
2.1 The mucosal immune system
Although the primary functions of the gastrointestinal mucosa are the digestion, absorption and
transport of water, electrolytes and nutrients, it also serves as an important mechanical barrier to
separate the host’s internal milieu from the external environment and prevent systemic contamina-
tion by microbes that are normally contained within the lumen of the gastrointestinal tract. However
the noninflamed mucosa also contains mononuclear cells. During intestinal infiltration large num-
bers of monocytes, macrophages and lymphocytes migrate into the lamina propria and produce
proinflammatory cytokines (IL-1b, IL-2, IL-6, TNFa) and chemokines (IL-8). Alone and in combi-
nation these mediators attract and activate further inflammatory cells. The process serves as an early
signalling system to amplify the mucosal inflammatory response in the early stages of bacterial in-
fection. The inflammatory mediator production can lead to local attack against microbes and sys-
temic acute phase reaction. Moreover, some cytokines like IL-1a, IL-1b and IL-6 have effect on
central nervous system modulating the release of various hormones, e.g. ACTH via activating the
hypothalamic-pitutiary-adrenocortical axis. Increased ACTH release results in glucocorticoid syn-
thesis which causes decreased cytokine production. This negative feedback loop plays an important
role in the regulation of inflammatory process.
It is supposed that intestinal epithelial cells are involved in immune response. Human colon epithe-
lial cells in vitro can process and present antigens to T cells (Mayer, 1987), and the human colon
epithelium in vivo and in vitro can be stimulated to express HLA class II (Mayer, 1991) and adhe-
sion molecules (Kelly, 1992). In addition, human colon epithelial cells and cell lines produce neu-
trophil chemoattractant proinflammatory chemokines e.g. IL-8 (Eckmann, 1993) and monocyte-
chemoattractant protein 1 (MCP-1) (Reinecker, 1995).  Moreover, human colon epithelial cell lines
express TGFb1 (Eckmann, 1993; Anzano, 1989), complement proteins like C3, C4, Factor B (An-
doh, 1993) and leukotrienes that might be involved in initiation and regulation of mucosal inflam-
matory process (Dias, 1992). Human colon epithelial cell lines can also respond to proinflammatory
cytokine-stimulation e.g. IL-1 (Raitano, 1993), TNFa (Fantini, 1992), IFNg (Phillips, 1990) and
TGFb1 (Mulder, 1990) with altered gene expression.
4Figure 1. Interaction of inflammatory and epithelial cells during mucosal inflammation (simpli-
fied scheme).
Immune cells like granulocytes, monocytes, macrophages and lymphocytes infiltrate the inflamed
mucosa. These cells produce various inflammatory mediators like IL-1b, IL-6, IL-2 and TNFa. This
production has an effect on epithelial cells. These cells response to the expressed cytokines by pro-
ducing inflammatory chemokines like IL-8 and MCP-1 recruiting more inflammatory cells.
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52.2 The inflammatory bowel disease
In the normal mucosa where the barrier function is intact the inflammatory mediator-production by
either intestinal epithelial cells or lymphoid cells is in repose. In inflammatory bowel disease this
balance is disturbed, the proinflammatory cytokines and chemokines are overexpressed. IL-1, IL-6,
granulocyte-macrophage CSF and TNFa have been reported to be increased in serum (Gross,
1991), cultures of biopsy tissues (Breese, 1993; Isaacs, 1992; Stevens, 1992) or isolated lamina
propria lymphocytes (Mahida, 1989; Simon, 1989) from patients suffering from inflammatory
bowel disease. This process causes a damage of the gastrointestinal mucosa and loss of epithelial
functions; e.g. the combination of TNFa and IFNg is cytotoxic for the colon epithelial cell line, HT-
29 (Deem, 1991). IL-1b up-regulates IL-6 synthesis by colon epithelial cells (Panja, 1995). IL-1b
also is an important acute phase mediator while IL-6 is the main mediator of acute phase reaction
(Heinrich, 1990).
Moreover, IL-1b has particularly important role in the process, being one of the most abundantly
secreted inflammatory mediators in IBD, produced by activated macrophages, epithelial cells, T-
and B-cells.
The etiology of inflammatory bowel disease is less known, it is characterized by a culmination of a
cascade of events and processes initiated by antigen. This antigen-driven response may be an ap-
propriate one directed against a persistently abnormal stimulus (e.g. a structural alteration of the
intestine or a causative agent in the environment), or an inappropriate response to otherwise in-
nocuous antigen (i.e., aberrant regulation of the immune response) (Podolsky, 1991).
The inflammatory bowel disease has two forms: ulcerative colitis and Crohn’s disease. Ulcerative
colitis involves only the mucosal surface of the colon resulting in diffuse friability and erosions
with bleeding. Crohn’s disease can develop in any part of gastrointestinal tract, most frequently in
the small intestine. In Crohn’s disease the whole intestinal wall is involved unlike ulcerative colitis,
resulting in mucosal inflammation and ulceration, stricturing, fistulous development and abscess
formation. Both diseases can be characterised by periods of symptomatic flare-ups and remissions
(Current Medical Diagnosis & Treatment, 1996).
Although all over the world many people suffer from inflammatory bowel disease, there are still no
specific therapies for this illness. Glucocorticoids remain the most potent drugs. Despite the effi-
cacy of glucocorticoids, almost 20% of the patients do not respond well to the therapy: 18% of the
patients suffering from ulcerative colitis proved to be steroid resistant after the first, standard, five
day long glucocorticoid therapy and 50% of them had recurrence of symptoms during the next 3
year long observation (Truelove, 1988). The statistics of Crohn’s disease are very similar: 20% of
6the patients were resistant during the standard 3 week long therapy and 55% of them became steroid
dependent or resistant through the next year (Munkholm, 1994).
Steroid-dependency is the other serious problem of glucocorticoid therapy. In case of some patients
only high dose of glucocorticoids can avert the flare-up of disease. But application of high dose of
glucocorticoids can have strong side effects, e.g. diabetes, osteoporosis or Cushing-syndrome.
2.3 The effects of glucocorticoids
Glucocorticoids have long been used as effective immunsuppressive agents in the treatment of cell-
or cytokine/chemokine mediated tissue damage. These drugs have been described to inhibit in-
flammation, suppress immune system activation and act as growth inhibitory agents both in vitro
and in vivo (Cupps, 1982). There are many observations concerning their effects: they induce a
rapid redistribution of lymphocytes from the circulation to other lymphoid compartments, lympho-
cyte apoptosis (Wyllie, 1980) the clonal expansion of T-cells and secretion of cytokines (Smith,
1980; Cupps, 1982). Interestingly, T-cells treated with exogenous IL-2 are able to proliferate in
response to mitogenic stimulation in presence of glucocorticoid drugs (Gillis, 1979). Moreover glu-
cocorticoids can repress the de novo transcription of many cytokine genes as IL-1, IL-6, TNFa and
IFNg (Taniguchi, 1988; Culpepper, 1987; Cupps, 1982). The expression of lipocortin-1, an inhibitor
of phospholipase-A2 is up-regulated by glucocorticoids, resulting in a decrease of prostaglandin E2
synthesis in many kinds of cells, including epithelial cells (Croxtall, 1994). There are only some
data concerning effect of glucocorticoids on gastrointestinal epithelium; they stabilize epithelial
functions (Urayama, 1998) and restore Na+-absorption in chronically inflamed epithelium (Sun-
dram, 1999). In addition glucocorticoids inhibit IL-1b mediated MCP-1 expression (Reinecker,
1995) and IFNg induced nitric oxide synthesis in the colon carcinoma cell line, Caco-2 (Chaves,
1999).
72.4 The mechanism of glucocorticoid receptor action
Glucocorticoid action is mediated by intracellular glucocorticoid receptors. These molecules are
members of the steroid hormone receptor family, all of which contain a homologous DNA binding
domain and divergent C-terminal ligand binding domains (Beato, 1989; Evans, 1988). The gluco-
corticoid receptor was first identified in rat thymocytes (Munck, 1968). During the last years its
molecular properties have been characterised and the gene encoding the receptor has been cloned
(Hollenberg, 1985; Miesfeld, 1986).
Two human receptor isoforms were identified (Hollenberg, 1985), hGRa and hGRb. They are syn-
thesized by alternative splicing, the first 727 amino acids are common. The a isoform contains 777
amino acids, the b form 742 amino acids long. The hGRa binds hormone and seems to be the major
physiological form (Hollenberg, 1985), hGRb is supposed to be an endogenous inhibitor of gluco-
corticoid action (Bamberger, 1995).
The inactive form of hGRa resides primarily in the cytoplasma associating with heat shock pro-
teines (hsp90 and hsp70) and one p59 immunophilin molecule (Pratt, 1993; Guiochon-Mantel,
1996). When glucocorticoid binds to its receptor, the complex dissociates and the liganded receptor
migrates into the nucleus. Here it interacts with promoter regions of different genes carrying gluco-
corticoid receptor responsive elements and modifies their expression. Interestingly, some research-
ers found both liganded and nonliganded forms to be present only in the nucleus (LaFond, 1988;
Raddatz, 1996).
2.5 Immunsuppressive effects of glucocorticoids, the transrepression of NF-kB
Glucocorticoids either induce gene transcription by interacting with specific DNA-elements (trans-
activation) or interfere with other transcription factors and inhibit their activity (transrepression).
Not many target genes carrying glucocorticoid receptor responsive elements are known until now.
Increasing expression has been reported concerning IkBa gene, encoding the inhibitory protein of
the main transcription factor for response to inflammatory cytokines, nuclear factor kappa B.
NF-kB, originally identified and named for its role in the regulation of immunoglobulin kappa
chain gene expression in B-cells (Lenardo, 1989; Sen, 1986), is a heterodimer that typically consists
of a p65 (RelA) and a p50 subunit (Baeuerle, 1989; Kawakami, 1988). The latent form resides in
the cytoplasma forming a complex with its inhibitory IkB proteins (Israel, 1995; Baldwin, 1996).
8Activation of NF-kB may occur through a variety of extracellular signals, which induce phospho-
rylation and ubiqutinylation events on IkBa, resulting in proteolytic degradation (Verma, 1995;
Finco, 1995; Bauerle, 1996). Then NF-kB is released from its inhibitor, translocates into the nu-
cleus and activates target genes. Numerous genes have been identified which are regulated by NF-
kB: cytokine (IL-1b, IL-2, TNFa) and chemokine (IL-8, MCP-1) encoding gene.  IkBa itself is
expressed in autoregulatory fashion: resynthesized and restored in the cytoplasma trapping the tran-
scriptionally active NF-kB molecules.
The immunsuppressive effect of glucocorticoids on NF-kB function may occur either via stimula-
tion of IkBa expression or via inhibition of migration of transcriptionally active NF-kB into the
nucleus. The latter effect is based on a direct protein-protein interaction between liganded hGRa
and active NF-kB because this complex can’t translocate to the nucleus  (Scheinman, 1995). How-
ever, recently it was reported that in the monocytic cell line THP-1 NF-kB is activated by dexa-
methasone (Wang, 1997) suggesting a cell specificity for this phenomenon.
9Figure 2. The mechanism of immunosuppression by glucocorticoids.
The inactive form of NF-kB localises in the cytoplasm forming a complex with IkB. Inflammatory
cytokines like IL-1b activate NF-kB which translocates to the nucleus, binds to NF-kB responsive
element carrying genes and increases the expression of various cytokines and chemokines. The ac-
tivated glucocorticoid receptor can bind to activated NF-kB and trap it in the cytoplasm.
2.6 Influence of cytokines on GR expression and function
Cytokines can influence the expression and function of glucocorticoid receptors in a number of cells
and tissues e.g. T-cells (Kam, 1993), monocytes and macrophages (Spahn, 1993; Falus, 1995),
bronchial cells and lung (Liu, 1993; Verheggen, 1996) and liver (Falus, 1995). Some of these stud-
ies have reported that cytokine treatment induces a decrease in glucocorticoid receptor function
(Kam, 1993; Liu 1993; Hill, 1986).
Pariante et al. described that in L929 mouse fibroblast cell line IL-1a disrupts translocation of the
glucocorticoid receptor from the cytoplasm to the nucleus (Pariante, 1999).
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These findings show that not only glucocorticoid hormones can have effect on cytokine expression
and function but, vice versa, inflammatory mediators also can modulate the effect of glucocorti-
coids, suggesting that a negative feedback loop reducing the efficacy of glucocorticoid hormones on
cellular level.
These experimental evidences may have important clinical consequences concerning acute and
chronic inflammatory diseases, e.g. asthma, sepsis, rheumatoid arthritis and the above mentioned
inflammatory bowel disease where glucocorticoid resistance has been found.
Because of the important role epithelial cells have in the process of IBD and the potential therapeu-
tic and physiological role glucocorticoids may have on epithelial cells, the aim of our work was to
characterize their glucocorticoid receptor signalling pathway. Since primary cells cannot be culti-
vated for longer time, we studied two different epithelial cell lines: the human colon carcinoma cell
line Caco-2 and rat intestinal cell line IEC-6. Both cell lines are well established cell culture models
for the intestinal epithelium (Jumarie, 1991; Jung, 1995; Quaroni, 1999).
Since inflammatory mediators are supposed to disturb GR signalling, our further aim was to test the
hypothesis that IL-1b, a major proinflammatory cytokine in IBD may inhibit glucocorticoid recep-
tor action.
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3. MATERIALS AND METHODS
3.1 Materials
3.1.1 Laboratory devices
Centrifuge Hettich Rotixa/K (Hettich Zentrifugen)
Centrifuge Sigma 3K30 (Sigma-Aldrich Chemie GmbH, Deisenhofen)
Centrifuge Sigma 5415D (Sigma-Aldrich Chemie GmbH, Deisenhofen)
Curix 60 film processor (Agfa-Geavert)
Environmental incubator shaker (New Brunswick Scientific Co. Inc. Edison)
GelCam digital control (Phase, Luebeck)
GeneQuant RNA/DNA Calculator (Pharmacia, Freiburg)
Heraeus Laminairâ (Heraeus Instruments GmbH, Hanau)
Heraeus Thermostat (Heraeus Instruments GmbH, Hanau)
Horizontal Gel Electrophoresis Apparatus HORIZONâ 11·14 (GIBCO BRL, Grand Is-
land)
Laboratory microscope Axiovert 25 Zeiss (Zeiss, Oberkochen)
Microplate Reader MRX Dynatech (Dynatech Technologies GmbH, Denkendorf)
Minishaker MS1 (Rettberg, Goettingen)
Omnigene Temperature Cycling System (Hybaid Limited, Teddington)
Power supply PowerPac 300 (Bio-Rad, Hercules)
Power supply PowerPac 200 (Bio-Rad, Hercules)
Precisious scale Sartorius (Sartorius AG, Goettingen)
Ready Gel Cell (Bio-Rad, Hercules)
Shaking platform Heidolph Polimax 2040 (Heidolph)
Thermomixer comfort (Eppendorf-Netheler-Hinz GmbH, Hamburg)
Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, Hercules)
Transilluminator 2020E (Stratagene, La Jolla)
Wallac 1409 liquid scintillation counter (Wallac distribution GmbH, Freiburg)
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3.1.2 Tools
6 well plates (Nunc, Rushilde)
24 well plates (Nunc, Rushilde)
75 cm culture flasks (Nunc, Rushilde)
96 well plates (Nunc, Rushilde)
Curix film cassette (Eastman Kodak Company, Rochester)
Eppendorf tubes (Eppendorf-Netheler-Hinz GmbH, Hamburg)
Lab-Tek Permanox eight-chamber slides (Nunc, Rushilde)
Nitrocellulose membrane (Novex, Frankfurt)
QIAshredder (QUIAGEN GmbH, Hilden)
Tissue culture dishes (60/15 mm, Cellstar) (Greiner GmbH, Frickenhausen
Tris-Glycine Ready Gel for SDS PAGE, 7.5% (Bio-Rad, Hercules)
X-OMAT autoradiograpy film (Eastman Kodak Company, Rochester)
3.1.3 Cells
Caco-2 from human colon adenocarcinoma (Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH, Braunschweig)
IEC-6 from rat normal small intestine (American Type Culture Collection, Rockville)
3.1.4 Chemicals
 [1,2,4-3H]Dexamethasone (Amersham Pharmacia Biotech, Freiburg)
1,4-dithiothreitol /DTT/ (GIBCO BRL, Grand Island)
2’-deoxynucleoside 5’-triphosphates /dNTP Mix/ (Roche Molecular Biochemicals, Mannheim)
2-mercaptoethanol (Merck KGaA, Darmstadt)
2-propanol (Merck KGaA, Darmstadt)
7.5% SDS polyacrylamide gel (Novex, Frankfurt)
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Agarose (GIBCO BRL, Grand Island)
Albumin / from bovine serum, fatty acid free/ (Roche Molecular Biochemicals, Mannheim)
Albumin /from bovine serum/ (Bio-Rad, Hercules)
Aminoacetic acid /glycin/ (Sigma-Aldrich, Deisenhofen)
Ampicillin (Sigma-Aldrich, Deisenhofen)
Bacto-agar (DIFCO, Detroit)
Bacto-tryptone (DIFCO, Detroit)
Bacto-yeast extract (DIFCO, Detroit)
Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules)
Dexamethasone (Sigma-Aldrich, Deisenhofen)
Diazobicyclooctan /DABCO/ (Sigma-Aldrich, Deisenhofen)
Dilution buffer for PCR (Roche Molecular Biochemicals, Mannheim)
Dimethyl Sulphoxide /DMSO/ (Sigma-Aldrich, Deisenhofen)
Di-Sodium hydrogen phosphate /Na2HPO4/ (Merck KGaA, Darmstadt)
Dulbecco’s modified Eagles’s medium /DMEM/ (Biochrom KG, Berlin)
Eagle’s minimal essential medium /EMEM/ (BioWhittaker, Verniers)
Ethanol absolut (Merck KGaA, Darmstadt)
Ethidium bromide (Sigma-Aldrich, Deisenhofen)
Ethylenediaminetetraacetic acid /EDTA/ (Sigma-Aldrich, Deisenhofen)
Ethyleneglycol-bis(b-aminoethylether)N,N,N’,N’-tetraace-
tic acid /EGTA/ (Sigma-Aldrich, Deisenhofen)
Fetal calf serum (GIBCO BRL Grand Island)
Fluorescein linked anti-mouse IgG (Amersham Pharmacia Biotech, Freiburg)
Fluorescein linked anti-rabbit IgG (Amersham Pharmacia Biotech, Freiburg)
Fluoromount-G (Southern Biotechnology, Birmingham)
FuGENETM 6 Transfection Reagent (Roche Molecular Biochemicals, Mannheim)
Gelatine (from bovine skin) (Sigma-Aldrich, Deisenhofen)
Glucose (Sigma-Aldrich, Deisenhofen)
Glycerol (Merck KGaA, Darmstadt)
Hydrochloric acid /HCl/ (Merck KGaA, Darmstadt)
Insulin /from porcine pancreas/ (Sigma-Aldrich, Deisenhofen)
Interleukin-1b /human/ (Roche Molecular Biochemicals, Mannheim)
Kanamycin (Sigma-Aldrich, Deisenhofen)
Magnesium sulphate /MgSO4/ (Merck KGaA, Darmstadt)
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Methanol (Merck KGaA, Darmstadt)
Mineral oil (Sigma-Aldrich, Deisenhofen)
Moloney Murine Leukemia Virus Reverse Transcriptase
/M-MLV-RT/ (Roche Molecular Biochemicals, Mannheim)
Mouse monoclonal antibody BuGR2 (Affinity BioReagents, Neshanic Station, NJ)
N-2 (hydroxyethyl) piperazine-N’-(2-ethanesulfonic acid)
/HEPES/ (Sigma-Aldrich, Deisenhofen)
Non essential amino acids (BioWhittaker, Verniers)
Nonidet NP-40 (Sigma-Aldrich, Deisenhofen)
Paraformaldehyde (Sigma-Aldrich, Deisenhofen)
Penicillin/Streptomycin (GIBCO BRL Grand Island)
Phenylmethansulfonyl fluoride /PMSF/ (Sigma-Aldrich, Deisenhofen)
Polyoxyethylenesorbitan monolaurate /Tween 20/ (Sigma-Aldrich, Deisenhofen)
Potassium chloride /KCl/ (Merck KGaA, Darmstadt)
Potassium dihydrogen phosphate /KH2PO4/ (Merck KGaA, Darmstadt)
Rabbit polyclonal antibody GR /P-20/ (Santa Cruz Biotechnology, Inc.)
Primer for cDNA Synthesis /p(dT)15/ (GIBCO BRL Grand Island)
RPMI-1640 (BioWhittaker, Verniers)
RU 486 (Mifepristone) (Exelgyn, Paris)
Scintillation fluid (Hirschmann, Eberstadt)
Sodium chloride /NaCl/ (Merck KGaA, Darmstadt)
Sodium dodecyl sulphate /SDS/ (Sigma-Aldrich, Deisenhofen)
Sodium hydroxide solution /NaOH/ (Merck KGaA, Darmstadt)
Sodium pyruvate (GIBCO BRL Grand Island)
Taq DNA Polimerase (Roche Molecular Biochemicals, Mannheim)
t-Octylphenoxypolyethoxyethanol /Triton X-100/ (Sigma-Aldrich, Deisenhofen)
Trypsin/EDTA (BioWhittaker, Verniers)
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3.1.5 Solutions
1.5 % agarose gel:
agarose 1.5 % (w/v)
ethidium bromide 0.4 µg/ml
---------------------------------------------
in TBE buffer
Blotting buffer for Western blot:
Tris base 25 mM
Glycin  50 mM
Methanol  5M
----------------------------------------
in distilled water
Buffer “A” for protein isolation:
HEPES pH 7.9 10 mM
KCl 10 mM
EDTA 0.1 mM
EGTA 0.1 mM
DTT 1 mM
PMSF                               1 mM
-------------------------------------------
in distilled water
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Buffer “B” for protein isolation:
HEPES pH 7.9 20 mM
NaCl 0.4 M
EDTA 1 mM
EGTA 1 mM
DTT 1 mM
PMSF 1 mM
----------------------------------------
in distilled water
Dilution buffer for PCR:
Tris-HCl 20 mM
Dithiotreitol 1 mM
EDTA 0.1 mM
KCl 0.1 mM
Nonidet P40 0.5 % (v/v)
Tween 20 0.5 % (v/v)
glycerol 50% (v/v)
 ---------------------------------------------
pH 8.0
Luria-Bertani agar plates:
bacto-agar 1.5 % (w/v)
ampicillin/kanamycin 50 µg/ml
---------------------------------------------
 in LB medium
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 Luria-Bertani /LB/ medium:
bacto-tryptone 1.0 % (w/v)
bacto-yeast extract 0.5 % (w/v)
NaCl 1.0 % (w/v)
----------------------------------------------
pH 7.0
in distilled water
Phosphate buffered saline /PBS/ solution:
NaCl   0.13 M
KCl     2.68 mM
Na2HPO4   10.2 mM
KH2PO4       1.5 Mm
-------------------------------------------
in distilled water
Running buffer for Western blot:
Tris base 20 mM
Glycin  0.2 M
SDS  40 mM
-----------------------------------------
in distilled water
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SOC medium:
bacto-tryptone 2.0 %
bacto-yeast extract 0.5 %
NaCl 10 mM
 KCl 2.5 mM
MgSO4 10 mM
glucose 20 mM
-----------------------------------------
in distilled water
TBE-buffer:
Tris base  0.1 M
Boric acid  0.1 M
EDTA pH 8 1 mM
---------------------------------------
in distilled water
3.1.6 Kits
ECL Western blotting analysis system (Amersham Pharmacia Biotech, Freiburg)
EndoFree Plasmid Maxi Kit (QUIAGEN GmbH, Hilden)
Original TA Cloning Kit (Invitrogen, Groningen)
RNeasy Mini Kit (QUIAGEN GmbH, Hilden)
SEAP Reporter Gene Assay Kit (Roche Molecular Biochemicals, Mannheim)
19
3.1.7 Primers
human GRa (Hollenberg, 1985) (MWG-BIOTECH GmbH, Edersberg):
5`-ACC AAT CAG ATA CCA AA ATA-3` (sense, coding position 2272-2291 of hGRa
cDNA)
5`-ATA CAC CAA CAG AAA GTC TA-3` (antisense, position 2716-2735)
human TNFa (Wang, 1985) (MWG-BIOTECH GmbH, Edersberg):
5`-GAG TGA CAA GCC TGT AGC CCA TGT TGT AGC A-3` (sense, position 404-
435)
5`-GCA ATG ATC CCA AAG TAG ACC TGC CCA GAC T-3` (antisense, position
847-816)
rat TNFa (Shirai, 1989) (CLONTECH Laboratories, Heidelberg):
5`-TAC TGA ACT TCG GGG TGA TTG GTC C-3` (sense, position 955-979)
5`-CAG CCT TGT CCC TTG AAG AGA AAC-3`(antisense, position 2180-2157)
3.1.8 Plasmid vectors
pBluescriptÒ SK +/- phagemid Vector (Stratagene, La Jolla, CA)
pCMV-IkBaM Vector (CLONTECH Laboratories, Heidelberg)
pGRE-SEAP Vector (CLONTECH Laboratories, Heidelberg)
pNFkB-SEAP Vector (CLONTECH Laboratories, Heidelberg)
pRShGRa Vector (Hollenberg, 1985) (American Type Culture Collection, Rockville)
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3.2 Methods
3.2.1 Cell culture conditions
Caco-2 cells were cultured in EMEM containing 20 % FCS, 1 % non-essential amino acids, 100
U/ml penicillin and 100 U/ml streptomycin at 37 °C under an atmosphere of 5 % CO2.
IEC-6 cells were cultured in combination of Dulbecco`s MEM and RPMI 1640 (1:1) containing
10 % FCS, 1 % sodium pyruvate, 100 U/ml penicillin and 100 U/ml streptomycin at 37 °C under an
atmosphere of 5 % CO2. 10-8 M insulin was freshly added to the cells every day.
Medium was changed every third day, the confluent cells were separated via Trypsin/EDTA treat-
ment.
3.2.2 Protein isolation for Western blot
Caco-2 and IEC-6 cells were grown in 75 cm culture flasks. 24 hours before drug treatment, 0.5 %
bovine serum albumin containing medium was added to the cells than they were incubated with 1
µM concentration of dexamethasone and/or 500 U/ml concentration of IL-1b.
Proteins were isolated from cells as described previously by E. Schreiber et al (Schreiber, 1989):
The cells were trypsinised, washed with PBS and pelleted by centrifugation. The pellet was resus-
pended in 1 ml PBS, transferred into an Eppendorf tube and pelleted again by spinning for 15 sec in
a microfuge. PBS was removed and the cell pellet was resuspended in 400 µl cold buffer “A” by
gentle pipetting in a yellow tip. The cells were allowed to swell on ice for 15 min, then 25 µl of a
10 % solution of Nonidet P-40 was added and the tube was vigorously vortexed for 10 seconds. The
homogenate was centrifuged for 30 sec. The cytoplasmic fraction containing supernatant was trans-
ferred into a fresh tube and stored in aliquots at –80 °C. The nuclear pellet was resuspended in 50 µl
ice-cold buffer “B” and the tube was vigorously rocked at 4 °C for 15 min on a shaking platform.
The nuclear extract was centrifuged for 5 min and the supernatant was frozen in aliquots at –80 °C.
The concentration of protein extract was measured according to the Bio-Rad protein assay method:
Increasing dilutions of bovine serum albumin standard containing from 20 to 500 mg/ml was pre-
pared. 100 ml from each protein standard or probe was added to an Eppendorf tube containing
1.25 ml 20 % of Dye Reagent. The mixture was vortexed and incubated for 10 minutes. 300 ml from
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each Eppendorf tube was transferred into a 96-plate and their absorbance was measured at 595 nm.
The absorbance at 595 nm versus concentration of standards was plotted, the unknown concentra-
tions were read from the curve.
3.2.3 Western blot
An aliquot containing 15 µg of protein was boiled in SDS and 2b-mercaptoethanol containing
loading buffer for 5 minutes and loaded into 7.5 % SDS polyacrylamide gel using 10 ng of recom-
binant human GR as positive control. SDS-polyacrylamide gel electrophoresis was performed using
Tris/Glycine/SDS containing running buffer. Proteins were transferred onto nitrocellulose mem-
brane for 30 minutes in blotting buffer in semidry transfer cell at 10 V. Filters were incubated for 1
hour with PBS/0.02 % Tween 20 containing 5 % non-fat dry milk at room temperature. After rins-
ing with PBS/Tween 20 the membrane was incubated overnight in case of Caco-2 with the rabbit
polyclonal antibody GR (P-20) at 1 mg/ml concentration, in case of IEC-6 with the mouse mono-
clonal antibody BuGR2 at 5 mg/ml concentration at 4 °C. This step was followed by washes with
PBS/Tween 20. After washing the membrane was incubated either with horseradish peroxidase-
conjugated anti-rabbit IgG (Caco-2 cells) or horseradish peroxidase-conjugated anti-mouse IgG
(IEC-6 cells) at 1:2000 dilution for 1 hour.
After further washes the immune complexes were visualised using ECL Western blotting analysis
system:
Equal volumes of detection solution 1 and detection solution 2 were mixed. The membrane was
covered by excess detection reagent and incubated without agitation for 1 minute at room tempera-
ture in dark room. The excess detection reagent was drained off and the membrane was transferred
in nylon foil pocket removing air bubbles and the nylon foil was placed in film cassette. A sheet of
autoradiograpy film was placed on top of the membrane, exposed for 1-5 minutes and developed
immediately.
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3.2.4 Immunostaining procedures
Caco-2 and IEC-6 cells were grown in Lab-Tek Permanox eight-chamber slides.
24 hours before drug treatment, 0.5 % bovine serum albumin containing medium was added to the
cells. Four different treatments were performed: with PBS as vehicle, IL-1b (500 U/ml) for 24
hours, dexamethasone (1 µM) for 1 hour and IL-1b (500 U/ml) for 24 hours followed by coincuba-
tion of IL-1b (500 U/ml) plus Dex (1 µM) for 1 hour.
After removal the medium the cells were washed twice in PBS, fixed in 2 % paraformaldehyde for
40 min at 37 °C and permeabilized in 0.3 % Triton X-100 dissolved in PBS for 10 min. Nonspecific
antibody binding was blocked by 0.2 % gelatine/PBS solution. Caco-2 cells were then incubated
with the rabbit polyclonal antibody GR (P-20) diluted in 0.2 % gelatine/PBS at 1µg/ml concentra-
tion, IEC-6 cells were incubated with the mouse monoclonal antibody BuGR2 at 5 µg/ml concen-
tration overnight at 4 °C. The following day Caco-2 cells were incubated with fluorescein linked
anti-rabbit IgG, IEC-6 cells were incubated with fluorescein linked anti-mouse IgG diluted in 0.2 %
gelatine/PBS at 1:200 dilution for 1 hour at 37 °C (in darkness). Two washes with PBS were per-
formed between all steps. Thereafter the cells were washed with distilled water followed by
mounting in Fluoromount.
3.2.5 Confocal laser scanning microscopy (CLSM)
Lab-Tek slides were viewed by fluorescence microscopy using a Zeiss LSM CLSM. One optical
section with a thickness of 1.2 µm was recorded through the centre of each visual field. Sections
were stored as digital pictures with a resolution of 512 ´ 512 pixels.
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3.2.6 Transformation of E. coli
Transformation of competent bacteria was performed according to manufacturers of Original TA
Cloning Kit.
2 µl of 0.5 M b-mercaptoethanol was pipetted into a 50 µl vial of melted One Shot INVaF´ com-
petent cells and mixed by stirring gently with the pipette tip. 500 ng of plasmid DNA was added
directly to the competent cells, mixed than incubated on ice for 30 minutes. Heat shock was per-
formed for 30 seconds in 42 °C water bath then the cells were placed on ice for 2 minutes. 450 µl of
SOC medium was added into the cells at room temperature and the vial was shaken horizontally at
37 °C for one hour at 225 rpm in a rotary-shaking incubator. Thereafter the vial with transformed
bacteria was placed on ice.
100 µl of transformed bacteria was spread on LB agar plate containing 50 µg/ml of ampicillin or
kanamycin. The agar plate was incubated at 37 °C for 18 hours.
3.2.7 Purification of plasmid DNA
Purification of plasmid DNA from transformed bacteria was performed according to manufacturers
of EndoFree Plasmid Maxi Kit.
A single colony of transformed bacteria was picked from the streaked LB agar plate and a 2 ml
starter culture of ampicillin containing LB medium was inoculated. The bacterial culture was incu-
bated for 12 hours at 37 °C with vigorous shaking at 300 rpm.
Thereafter the starter culture was diluted to 1:1000 and bacteria were grown at 37 °C for 16 hours
with shaking at 300 rpm.
The bacterial cells were harvested by centrifugation at 6000 g for 15 minutes at 4 °C. The medium
was removed and the pellet was resuspended in 10 ml Buffer P1. The cells were lysed by adding
10 ml Buffer P2 and the lysate was incubated at room temperature for 5 minutes. Genomic DNA,
proteins and cell debris was precipitated by 10 ml chilled Buffer P3 and filtered by QIAfilter Car-
tridge. The filtered lysate first was incubated on ice for 30 minutes after adding 2.5 Buffer ER then
applied to the anion-exchange resin containing QIAGEN-tip followed by two washed with 30 ml
Buffer QC. Plasmid DNA was eluted with 15 ml Buffer QN and precipitated by adding 10.5 ml
room-temperature isopropanol. The mixture was centrifuged immediately at 15000 g for 30 minutes
at 4 °C. After centrifugation the DNA pellet was washed with 70 % ethanol, pelleted at 15000 g for
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10 minutes. Thereafter the supernatant was disturbed and the pellet was air-dried. Finally DNA was
redissolved in 200-500 µl Buffer TE and its concentration was determined by spectrophotometry
measuring the absorbance at 260 and 280 nm.
3.2.8 Transient transfection of Caco-2 and IEC-6 cells
Caco-2 and IEC-6 cells were grown in 24 well plates at a density of 30000/well in 1 ml medium. 24
hours before the transfection 0.5 % bovine serum albumin containing medium was added to the
cells. The transfection was performed by non-liposomal formulation FuGENE according to manu-
facturer’s protocol. FuGENE was prediluted in 100 µl serum free medium (3 µl FuGENE/µg
DNA), then the concentrated plasmid DNA was added to the mixture. It was incubated for 15 min-
utes then pipetted into the wells containing 900 µl serumfree medium.
In transactivation experiments 200 ng of pGRE-SEAP/well, in transrepression studies 200 ng of
pNFkB-SEAP/well was added to the cells. In cotransfection examinations the cells were transfected
either with 1 µg pRShGRa expression vector or with 200 ng pCMV-IkBaM and 200 ng of appro-
priate reporter plasmid. In the control groups DNA content was equilibrated by pBluescipt vector.
In transactivation experiments different concentrations of dexamethasone (10-6 M - 10-9 M) and/or
10-6 M of RU 486 were added to the cells in presence of absence of IL-1b (5-500 U/ml) 24 hours
post transfection.
In transrepression studies the cells were treated with different doses of IL-1b (5-500 U/ml) in pres-
ence or absence of 1µM concentration of dexamethasone 24 hours post transfection.
In both studies control cells were treated with appropriate amount of vehicles (PBS or ethanol). In
transactivation experiments the cells were incubated for 24 hours, in transrepression assays for 6
hours. After this time media were collected to determinate the reporter gene activity.
25
3.2.9 SEAP Reporter Gene Assay
The quantification of alkaline phosphatase secreted by transfected cells is based on the phosphory-
lation of CSPD [3-(4-metoxyspiro[1,2-dioxetane-3,2’(5’-chloro)-tricyclo(3.3.1.1)decane]-4-
yl)phenyl-phosphate] by alkaline phosphatase. The resulting unstable dioxetane anion decomposes
and emits light with its maximum activity at 477 nm.
The alkaline phosphatase activity was determined according to protocol of SEAP Reporter Gene
Assay Kit.
50 µl aliquot of culture supernatant was centrifuged to pellet any debris then diluted 1:4 with Dilu-
tion Buffer followed by incubation for 30 minutes at 65 °C to heat-inactivate the endogenous alka-
line phosphatase activity. Thereafter samples were pelleted again, then 100 µl of supernatant was
transferred to a tube and the same amount of Inactivation Buffer was added. After 5 minutes incu-
bation 100 µl of Substrate Reagent was pipetted into the tube. The sample was rocked gently for 10
minutes. The chemiluminescent signal was counted in a liquid scintillation counter.
3.2.10. 3H-dexamethasone binding assay
Caco-2 and IEC-6 cells were grown in 6 well plates at a density of 500.000/well covered by serum-
free medium. The cells were treated with 50 nM concentration of 3H-dexamethasone in absence or
presence of 1000 fold molar excess of unlabeled steroid for two hours at 37 °C to determine total
and unspecific dexamethasone binding. After dexamethasone treatment the supernatant was re-
moved. The cells were first washed three times with ice cold PBS then harvested by 1ml 0.1 normal
NaOH. 1 ml 0.1 normal HCl was added to the cells to neutralize the pH. The 2 ml solutions were
transferred to scintillation tubes containing 8 ml of scintillation fluid and measured in a liquid scin-
tillation counter.
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3.2.11 RNA isolation
Caco-2 and IEC-6 cells were cultured in tissue culture dishes (60/15 mm, CellStar) at a density of
500 000/well in 3 ml medium. 24 hours before drug treatment, 0.5 % bovine serum albumin con-
taining medium was added to the cells than they were incubated with dexamethasone and/or IL-1b.
Total RNA isolation was performed according to RNeasy Mini Protocol.
The cells were first washed with 3 ml PBS than lysed in 500 µl highly denaturing guanidinium iso-
thiocyanate-containing buffer (Buffer RLT). RNases were inactivated by adding b-mercaptoethanol
to the buffer previously (10 µl/1ml Buffer RLT). The lysate was pipetted directly onto a QIAshred-
der column sitting in the 2 ml collection tube and centrifuged for 2 min at maximum speed to ho-
mogenise. 500 µl 70% ethanol was added to the homogenised lysate to provide appropriate binding
conditions and mixed well by pipetting. The lysate was applied to an RNeasy spin column in 500 µl
aliquots and centrifuged for 1 min at 10000 g. The membrane-bound RNA was washed first by pi-
petting 500 µl washing buffer (Buffer RW1) than by adding 500 µl ethanol containing Buffer RPE
onto the column and centrifuging for 1 min at 10000 g. The RNeasy membrane was dried by 500 µl
Buffer RPE centrifuging for 2 min at maximum speed and the column was transferred to a 1.5 ml
Eppendorf tube. 30 µl RNase-free water was added to the membrane and the RNA was eluted by
centrifuging for 1 min at 10000 g. The total RNA was stored at –80 °C.
The concentration of total RNA was determined by spectrophotometry measuring the absorbance at
260 and 280 nm. (An absorbance of 1 unit at 260 nm corresponds to 40 µg RNA per ml. This rela-
tionship is valid for measurements of water-diluted RNA.)
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3.2.12 RT-PCR
1 µg of total RNA was reverse transcribed to copy-DNA (cDNA) in a final volume of 40 µl con-
taining 200 U M-MLV reverse transcriptase, 50 mM Tris HCl pH 8.3, 75 mM KCl, 3 Mm MgCl2,
10 mM DTT, 10 µg7ml (dT)15-primer and 2 mM dNTP for 1 hour at 37°C.
RT-products were amplified by polimerase chain reaction in 25 ml PCR-mixture containing 1 ml
aliquot of cDNA, 0.2 mM each of sense and antisense primer, 1.5 mM MgCl2, 10 mM Tris-HCl,
50 mM KCl, 0.01 % gelatine, 0.8 mM dNTP, and 1 U Taq polymerase.
Using specific primer sequences for human GRa /5`-ACC AAT CAG ATA CCA AA ATA-3`
(sense, coding position 2272-2291 of hGRa cDNA) and 5`-ATA CAC CAA CAG AAA GTC TA-
3` (antisense, position 2716-2735)/, amplification was carried out by 38 cycles at 95 °C for 45 sec-
onds, 54 °C for 90 seconds and 72 C° for 90 seconds.
PCR reactions with human TNFa primer /5`-GAG TGA CAA GCC TGT AGC CCA TGT TGT
AGC A-3` (sense, position 404-435) and 5`-GCA ATG ATC CCA AAG TAG ACC TGC CCA
GAC T-3` (antisense, position 847-816)/ and with rat TNFa primer /5`-TAC TGA ACT TCG GGG
TGA TTG GTC C-3` (sense, position 955-979) and 3`-CAG CCT TGT CCC TTG AAG AGA
AAC-3`(antisense, position 2180-2157)/ were carried out by 40 cycles at 95 C° for 45 seconds,
60 C° for 45 seconds and 72 C° for 90 seconds.
PCR-products were electrophoresed in a 1.5 % agarose gel and visualised by ethidium bromide
staining.
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4. RESULTS
4.1 Glucocorticoid receptor expression in Caco-2 and IEC-6
To characterize the glucocorticoid receptor expression in Caco-2 and IEC-6 cells, Western blot
analysis was performed.
The results revealed that GR protein was expressed in both cell lines. In Caco-2 the specific band
comigrated with a recombinant human glucocorticoid receptor expressed in a bacuolvirus system
using as positive control (Figure 3.).
Both cytosolic and nuclear protein extracts were examined. In case of the human cell line Caco-2
the majority of GRs were detected in the nuclear extract, in the rat cells obvious cytosolic localisa-
tion was observed (Figure 4.).
Figure 3. Human GRa protein in Caco-2. Western blot analysis.
The presence of GRa was detected in cytosolic and nuclear extracts prepared from Caco-2 cells
using the polyclonal antibody P-20. Lane 1 and lane 3 show the recombinant GR, lane 2 demon-
strates the nuclear extract, lane 4 the cytoplasmic fraction. The additional bands may be degrada-
tion products.
94 kD
1 2 43
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Figure 4. Rat GR protein in IEC-6 . Western blot analysis.
The presence of GR was detected in cytosolic and nuclear extracts prepared from IEC-6 cells using
the monoclonal antibody BuGR2. Lane 1 shows the nuclear extract, lane 2 demonstrates the cyto-
plasmic fraction.
To characterize the functional activity of GR, radioligand-binding assay was performed using 3H-
dexamethasone. We detected 66400 ± 6700 specific binding sites/cell in Caco-2 and 99600 ± 15300
sites/cell in IEC-6. However, the unspecific binding in Caco-2 was very high, only 10 % of the total
binding was specific. So that the number of specific binding sites is probably overestimated.
95 kD
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4.2 The gene regulatory effects of glucocorticoids can be measured by transfection experi-
ments in intestinal epithelial cells
The transactivation effect of dexamethasone can be monitored by transfection with a reporter gene
construct carrying glucocorticoid receptor responsive (GRE) element. Glucocorticoid treatment
after transfection results in glucocorticoid receptor activation and increased transcription of the re-
sponsive element containing reporter gene.
In Caco-2 cells glucocorticoid receptor activation in presence of 1µM dose of dexamethasone re-
sulted in a 3.9 ± 0.5 fold (mean of fold induction ± SEM), in IEC-6 cells a 5.2 ± 0.4 fold induction
of reporter gene activity relative to the basal transcription. In both cell lines decreasing concentra-
tions of dexamethasone resulted in a dose dependent induction of SEAP activity, which was inhib-
ited by the competitive glucocorticoid receptor antagonist, RU-486. The antagonist alone had no
effect on SEAP activity (Figure 5. and Figure 6.).
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Figure 5. Effect of dexamethasone on transcriptional transactivation in Caco-2 cells.
Caco-2 cells were transiently transfected with pGRE-SEAP (200 ng/well) then incubated with de-
creasing concentrations of dexamethasone (10-6 M - 10-9 M) in absence or presence of RU 486
(10-5 M) for 24 hours. Alkaline phosphatase activities are shown relative to the level of SEAP activ-
ity of the control group treated with the vehicle substance ethanol alone.
Relative SEAP activities are demonstrated as means of fold induction over controls ± SEM for n=3.
The experiments were performed in duplicate.
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Figure 6. Effect of dexamethasone on transcriptional transactivation in IEC-6 cells.
IEC-6 cells were transfected with pGRE-SEAP (200 ng/well) then incubated with decreasing con-
centrations of dexamethasone (10-6 M - 10-9 M) in absence or presence of RU 486 (10-5 M) for 24
hours. Reporter gene activities are shown as compared to the level of SEAP activity of control
group treated with the vehicle substance ethanol alone.
Relative SEAP activities are demonstrated as means of fold induction over controls ± SEM for n=3.
Each experiment was performed in duplicate.
The transrepressive effect of dexamethasone was measured by transfection with the NF-kB respon-
sive element carrying reporter gene construct pNF-kB-SEAP.
As it is demonstrated in the figures below, IL-1b, a known NF-kB activating agent induced a dose
dependent increase in NF-kB mediated reporter gene activity in both cell lines. In Caco-2 cells
5 U/ml concentration resulted in a 4.6 ± 0.8 fold, 50 U/ml caused 7.65 ± 0.3 fold, 500 U/ml 8.6 ±
0.2 fold increase of SEAP-activity (Figure 7.). In IEC-6 cells we found 2.8 ± 0.8 fold increase at
5 U/ml, 5.1 ± 0.3 fold increase at 50 U/ml, and 7.3 ± 0.3 fold increase at 500 U/ml concentration of
IL-1b (Figure 8.).
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Figure 7. IL-1b mediated NF-kB activation in Caco-2 cells.
Caco-2 cells were transfected with NF-kB responsive element carrying reporter gene construct
(pNF-kB-SEAP, 200 ng/well). 24 hours post transfection the cells were stimulated with increasing
concentrations of IL-1b (5-500 U/ml) for 6 hours. Then media were collected and the reporter gene
activities were measured. Transcriptional activities of SEAP are shown as relative to controls (PBS
treated cells). Relative SEAP activities represent means of fold induction ± SEM for n=3. The ex-
periments were performed in duplicate.
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Figure 8. IL-1b mediated NF-kB activation in IEC-6 cells.
IEC-6 cells were transfected with pNF-kB-SEAP (200 ng/well). 24 hours post transfection the cells
were stimulated with increasing concentrations of IL-1b (5-500 U/ml) for 6 hours. Thereafter media
were collected and SEAP activities were measured. SEAP activities are shown compared to control
cells, which received PBS. Relative SEAP activities represent means of fold induction ± SEM for
n=3. The experiments were performed in duplicate.
4.3 The transrepressive effect of dexamethasone on IL-1b  induced, NF-kB mediated reporter
gene activity in Caco-2 and IEC-6 cells
Surprisingly, in Caco-2 cells 1 µM dexamethasone had no influence on IL-1b induced, NF-kB me-
diated reporter gene activity. In this experiment the cells were coincubated with 1 µM dexameth-
asone and increasing concentrations of IL-1b (5-500 U/ml) for 6 hours. We found that Dex could
not decrease the IL-1b induced reporter gene activity at all. (Figure 9.).
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Figure 9. Effect of dexamethasone on IL-1b induced, NF-kB mediated SEAP activity in Caco-2
cells.
Caco-2 cells were transfected with pNF-kB-SEAP (200 ng/well) and treated with increasing con-
centrations of IL-1b (5-500 U/ml) in presence or absence of Dex (1 µM) for 6 hours. After the vari-
ous treatments media were collected and reporter gene activities were measured. They are shown
as relative activities compared control, which did not receive IL-1b. Relative SEAP activities are
presented as means of fold induction ± SEM for n=3. The experiments were performed in duplicate.
In contrast to Caco-2, in IEC-6 cells 1 µM dexamethasone could inhibit the NF-kB mediated SEAP
activity at each doses of IL-1b (5, 50 and 500 U/ml). In presence of dexamethasone the reporter
gene activity was 80 % ± 20 % at 5 U/ml of IL-1b, 60 % ± 6 % at 50 U/ml and 50 % ± 8.5 % at
500 U/ml compared to cells incubated without Dex.
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Figure 10. Effect of dexamethasone on IL-1b induced, NF-kB mediated SEAP activity in IEC-6
cells.
IEC-6 cells were transfected with pNF-kB-SEAP (200 ng/well) then incubated with increasing con-
centrations of IL-1b (5-500 U/ml) in presence or absence of Dex (1 µM) for 6 hours. After the
various treatments media were collected and SEAP activities were measured. The activities are
shown relative to PBS treated cells (control group). Relative SEAP activities are demonstrated as
means of fold induction ± SEM for n=3. The experiments were carried out in duplicate.
4.4 IL-1b  repressed the stimulating effect of dexamethasone on transactivation in both of
Caco-2 and IEC-6 cells
To test the influence of IL-1b on GR mediated reporter gene activity, Caco-2 and IEC-6 cells were
transfected with GRE carrying reporter gene construct pGRE-SEAP and stimulated with 1 µM
dexamethasone. Coincubation with increasing concentrations of IL-1b resulted in a reduced reporter
gene activity in both cell lines. IL-1b alone had no effect on SEAP activity (data not shown).
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In Caco-2 cells 5 U/ml dose of IL-1b resulted 57 % ± 6 % GR mediated reporter gene activity, at 50
U/ml 33 % ± 10 %, at 500 U/ml 19 % ± 3 % activity compared to SEAP activity of cells incubated
in absence of IL-1b (Figure 11.).
Figure 11. Effect of IL-1b on dexamethasone induced, GR mediated reporter gene activity in
Caco-2 cells.
Caco-2 cells were transfected with pGRE-SEAP reporter gene construct (200 ng/well), then stimu-
lated with increasing concentrations of IL-1b (5-500 U/ml) in presence of 1 µM dose of dexameth-
asone. After 24 hours media were collected and SEAP activities were measured. Reporter gene ac-
tivities of IL-1b- and dexamethasone-treated groups were compared to the control. Relative SEAP
activities are demonstrated as means of fold induction ± SEM for n=3. The experiments were per-
formed in duplicate.
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In IEC-6 cells the lowest dose of IL-1b (5 U/ml) resulted in a 53 % ± 6 % reporter gene activity, 50
U/ml of IL-1b caused a reduction to 50 % ± 5 %, 500 U/ml dose resulted in a decrease to 40 % ±
4 % activity compared to the cells treated with Dex alone (Figure 12.).
Figure 12. Effect of IL-1b on dexamethasone induced, GR mediated reporter gene activity in
IEC-6 cells.
IEC-6 cells were transfected with pGRE-SEAP reporter gene construct (200 ng/well), then stimu-
lated with increasing concentrations of IL-1b (5-500 U/ml) in presence of 1 µM dexamethasone for
24 hours. After incubation media were collected and SEAP activities were measured. Reporter gene
activities of IL-1b- and dexamethasone-treated groups were compared to the control. Relative
SEAP activities are demonstrated as means of fold induction ± SEM for n=3. Each experiment was
performed in duplicate.
1 2 3 4 5
0
1
2
3
4
fo
ld
 in
du
ct
io
n
Dex 1 µM            -          +         +         +         +
IL-1b (U/ml)       -           -         5         50      500
39
4.5 IL-1b  inhibits glucocorticoid receptor translocation
The insufficiency of dexamethasone in presence of IL-1b regarding both transactivation and trans-
repression in Caco-2 and IEC-6 cells supposed that the glucocorticoid receptor action is disturbed in
presence of the cytokine.
To confirm our findings, GR translocation from cytoplasm to nucleus was examined using GR im-
munostaining.
As it is demonstrated on the figures below, mainly nuclear staining could be observed in the vehicle
treated Caco-2 cells, neither IL-1b nor dexamethasone treatment changed the pattern of GR staining
(Figure 13).
Figure 13. GR immunostaining after treatment with Dex and/or IL-1b in Caco-2 cells.
Caco-2 cells were treated with vehicle, Dex (1 µM) for 1 hour, IL-1b (500 U/ml) for 24 h followed
by coincubation with IL-1b (500 U/ml) and Dex (1 µM) for 1 h and IL-1b (500 U/ml) for 24 h. GRs
were immunostained with rabbit anti-GR polyclonal antibody P-20 (1µg/ml). Optical sections (1.2
µm) were recorded by CLSM.
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In vehicle treated control IEC-6 cells the fluorescent signal was more intense in the cytoplasm than
in the nucleus, a ring-shaped perinuclear localisation could be observed.
After Dex treatment cells presented more intense nuclear staining, confirming that incubation with
dexamethasone induced GR translocation from the cytoplasm to the nucleus.
Coincubation with Dex and IL-1b resulted in a complete inhibition of GR translocation.
Finally, treatment with IL-1b alone had no apparent effect on the pattern of GR staining
(Figure 14.).
Figure 14. Immunostaining of GR after treatment with Dex and/or IL-1b in IEC-6 cells.
IEC-6 cells were treated with vehicle, Dex (1 µM) for 1 hour, IL-1b (500 U/ml) for 24 h followed by
coincubation with IL-1b (500 U/ml) and Dex (1 µM) for 1 h and IL-1b (500 U/ml) for 24 h. GR
protein was stained with mouse monoclonal antibody BuGR2 (5 µg/ml). Optical sections (1.2 µm)
were recorded by CLSM.
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4.6 IL-1b  does not reduce dexamethasone binding in Caco-2 and IEC-6
Our findings presented above confirm the observation that the proinflammatory cytokine, IL-1b
reduces glucocorticoid receptor function.
To answer the question whether IL-1b downregulates glucocorticoid receptor quantity, radiobinding
assays were performed. GR-levels were measured in Caco-2 and IEC-6 cells treated with IL-1b
(500 U/ml) or vehicle.
As it is demonstrated in the figures below, there was no apparent change in the glucocorticoid re-
ceptor numbers.
Figure 15. Specific binding of 3H- dexamethasone to Caco-2 and IEC-6 cells. Influence of IL-1b
treatment.
Caco-2 and IEC-6 cells were incubated with IL-1b (500 U/ml) or PBS (vehicle substance) at 37 °C
for 24 hours, then treated with 50 nM concentration of 3H-dexamethasone in absence or presence
of 1000 fold molar excess of unlabeled steroid for two hours. The total and unspecific Dex binding
was measured in a liquid scintillation counter.
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4.7 Dexamethasone can reduce the IL-1b-induced TNFa expression only in IEC-6 cells but
not in Caco-2
Based on the observation that LPS significantly increased the production of TNFa in Caco-2 cells
(Ogle, 1997), we asked the question whether IL-1b can induce TNFa expression and this cytokine
production can be inhibited by dexamethasone in Caco-2 and IEC-6 cells.
To answer the question RT-PCR experiments were performed using human and rat TNFa primers.
The cells were incubated with vehicle (1), Dex (1 µM) (2), IL-1b (500 U/ml) (3) and combination
of IL-1b and Dex (4) for 4 hours. After the various treatments total RNAs were isolated and RT-
PCR was performed (Figure 16.).
Nonstimulated Caco-2 cells did not express TNFa, IEC-6 cell did. 500 U/ml concentration of IL-1b
stimulated the cytokine expression in both cell lines, in Caco-2 the effect was more intense than in
IEC-6. 1 µM dose of dexamethasone had effect only on TNFa expression produced by IEC-6, in
Caco-2 Dex could not inhibit the production of TNFa mRNA.
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Caco-2 IEC-6
Figure 16. Effect of dexamethasone on TNFa mRNA expression induced by IL-1b in Caco-2 and
IEC-6 cells.
Caco-2 and IEC-6 cells were incubated with vehicle (1), Dex (1 µM) (2), IL-1b (500 U/ml) (3) and
combination of IL-1b and Dex (4) for 4 hours. Thereafter total RNA was isolated and copy DNA
was prepared. RT-PCR was performed using specific TNFa primers. PCR products were run on
1.5 % agarose gel and visualised with ethidium bromide. The figures show one representative result
out of three independent experiments.
4.8 Glucocorticoid receptor action could be restored by increasing the receptor content by
GR-overexpression in Caco-2
As Caco-2 cells were apparently endowed with less GRs than IEC-6 cells we hypothesised that in-
crease of the receptor content may result more sufficient glucocorticoid receptor action.
To increase the receptor quantity, Caco-2 cells were transfected with glucocorticoid receptor-
overexpression vector (pRShGRa) (Hollenberg, 1985). To examine the effect of pRShGRa on
quantity of glucocorticoid receptor mRNA, Caco-2 cells were grown in 6 cm tissue culture dishes at
a density of 600000/well in 3 ml medium, transfected with 9 µg pRShGRa vector then total RNA
was isolated. The GR mRNA expression was determined by RT-PCR. As it is demonstrated in Fig-
ure 17., glucocorticoid receptor mRNA was increased after transfection with overexpression vector.
444 bp
295 bp
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Figure 17. RT-PCR of hGRa mRNA: increased glucocorticoid receptor mRNA after transfection
with pRShGRa vector in Caco-2 cells.
Caco-2 cells were transfected with glucocorticoid receptor overexpression vector (pRShGRa, 9
µg), then total RNA was isolated. 1 µg of total RNA was reverse transcribed to RT, then RT-PCR
was performed. The first band (1) shows hGR mRNA content in untreated cells, the second band (2)
shows the hGR mRNA production in pRShGRa transfected cells. Copy DNA of negative controls (3
and 4) were prepared in absence of M-MLV reverse transcriptase to exclude DNA contamination.
PCR products were run on 1.5 % agarose gel and visualised with ethidium bromide. On the figure
one result out of three independent experiments is demonstrated.
To confirm that pRShGRa really increased the receptor content in Caco-2 cells, the following step
was to test the transactivating effect of dexamethasone on GR-overexpressing cells.
Cotransfection with pRShGRa and pGRE-SEAP followed by treatment with decreasing concentra-
tions of dexamethasone resulted a significant, dose dependent increase in reporter gene activity
(1 mM Dex caused 16.3 ± 0.6 fold induction) (Figure 18.). In absence of dexamethasone GR over-
expression had no effect on SEAP activity.
1 2 3 4
596 bp
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Figure 18. Effect of dexamethasone on transactivation in Caco-2 cells overexpressing glucocor-
ticoid receptor.
Caco-2 cells were cotransfected with pRShGRa overexpression vector (1 µg/well) and pGRE-SEAP
(200 ng/well) then incubated with decreasing concentrations (10-6 M - 10-9 M) of dexamethasone
for 24 hours. In controls DNA amount was equilibrated by pBluescript vector (1 µg/well).
Reporter gene activities are shown as compared to the level of SEAP activity of the control group
transfected with pBluescript and treated with ethanol as vehicle substance.
Relative SEAP activities are presented as means of fold induction over controls ± SEM for n=3. The
experiments were performed in duplicate.
Coincubation with IL-1b (500 U/ml) and Dex (1 µM) could repress the transactivating effect in
receptor overexpressing Caco-2 compared to cells treated with 1 µM Dex alone, but the decrease
was not as dramatic as in cells containing the normal receptor level. In cells with basal GR content
20 % ± 9,5 % reporter gene activity was observed after coincubation with Dex and IL-1b, in GR
overexpressing cells 75 % ± 2 % activity was detected compared to cell treated with Dex. IL-1b
alone had no effect on GR mediated transactivation. (Figure 19.).
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Figure 19. Effect of IL-1b on dexamethasone induced, GR mediated reporter gene activity in GR
overexpressing Caco-2 cells.
Caco-2 cells were cotransfected with pRShGRa (1 µg/well) and pGRE-SEAP (200 ng/well), then
incubated with 1 µM dexamethasone for 24 hours in presence or absence of 500 U/ml concentra-
tion of IL-1b. DNA amount was equilibrated by pBluescript vector (1 µg/well). Reporter gene ac-
tivities were compared to the control. Relative SEAP activities are demonstrated as means of fold
induction ± SEM for n=3, the experiments were performed in duplicate.
The transrepressive regulatory effect of Dex also could be restored by GR overexpression.
Caco-2 cells were cotransfected with pRShGRa (1 µg/well) and pNFkB-SEAP (200 ng/well) then
incubated with IL-1b (500 U/ml) for 6 hours.
We found that spontaneous NFkB mediated reporter gene activity was reduced to 60% ± 3 % in
GR-overexpressing cells compared to controls transfected with pBluescript. Incubation with 1µM
dexamethasone resulted in a further decrease (44 % ± 4 %).
500 U/ml IL-1b stimulated the reporter gene activity. In Caco-2 cells transfected with pBluescript
dexamethasone could not repress the IL-1b mediated NF-kB activity at all, but in GR overexpress-
ing cells Dex reduced NF-kB activity compared to cells treated with IL-1b alone (Figure 20.).
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Figure 20. Effect of dexamethasone on IL-1b induced, NF-kB mediated SEAP activity in GR
overexpressing Caco-2 cells.
Caco-2 cells were cotransfected with pRShGRa (1 µg/well) and pNF-kB-SEAP (200 ng/well) and
coincubated with 1 µM Dex and 500 U/ml concentration of IL-1b) for 6 hours. In control groups
DNA amount was equilibrated by pBluescript vector (1 µg/well). Reporter gene activities were
compared to the activity of control cells transfected with pBluescript. Relative reporter gene activi-
ties are shown as means of fold induction ± SEM for n=3.  The experiments were performed in du-
plicate.
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4.10 NF-kB is not responsible for the impairment of glucocorticoid receptor action in Caco-2
As a direct protein-protein interaction between liganded hGRa and active NF-kB was observed in
Hela cells (Scheinman, 1995), our conception was that this physical connection can be involved in
the impairment of GR action in Caco-2. Under normal conditions glucocorticoid receptors can in-
hibit the NF-kB activity via protein-protein binding, but in presence of a high amount of transcrip-
tionally active NF-kB all the glucocorticoid receptors may be blocked.
To test the hypothesis that NF-kB really plays a role in this process, Caco-2 cells were transfected
with the pCMV-IkBaM vector. The plasmid construct encodes a mutant form of IkBa with a ser-
ine-to-alanine mutation at residues 32 and 36. This variant is not capable to dissociate from NF-kB-
IkB complex so that in cells overexpressing the mutant IkB form the NFkB-pathway can be
blocked.
Caco-2 cells were cotransfected with pCMV-IkBaM (200 ng/well) and pNF-kB-SEAP (200
ng/well) then incubated with 500 U/ml dose of IL-1b. Figure 21. demonstrates that in presence of
pCMV-IkBaM IL-1b could not increase the NF-kB mediated reporter gene activity at all showing,
that the NF-kB-pathway is successfully blocked.
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Figure 21. IL-1b induced, NF-kB mediated reporter gene activity in IkBa overexpressing Caco-2
cells.
Caco-2 cells were cotransfected with pCMV-IkBaM (200 ng/well) and pNF-kB-SEAP (200
ng/well), then incubated with 500 U/ml of IL-1b for 6 hours. In control groups DNA amount was
equilibrated by pBluescript vector (200 ng/well). Reporter gene activities were compared to the
activity of control cells transfected with pBluescript. Relative reporter gene activities are presented
as means of fold induction ± SEM for n=3, the experiments were performed in duplicate.
To answer the question if glucocorticoid receptor action can be restored by blocking the NF-kB
activity via IkB overexpression, Caco-2 cells were cotransfected with pCMV-IkBaM and pGRE-
SEAP then incubated with 1 µM dexamethasone in presence or absence of IL-1b (500 U/ml).
As it is shown in Figure 22., the glucocorticoid receptor action was not restored by blocking the
NF-kB-pathway in Caco-2 cells since IkB overexpression was not capable of reversing the Dex
induced transactivation disturbed by IL-1b.
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Figure 22. Dexamethasone induced, GR mediated transactivation in presence of IL-1b in IkBa-
overexpressing Caco-2 cells.
Caco-2 cells were cotransfected with pCMV-IkBaM (200 ng/well) and pNF-kB-SEAP (200 ng/well)
and incubated with 1 µM Dex in presence or absence of IL-1b (500 U/ml) for 24 hours. In control
groups DNA amount was equilibrated by pBluescript vector (200 ng/well). Reporter gene activities
were compared to the activity of control cells transfected with pBluescript. Relative reporter gene
activities are presented as means of fold induction ± SEM for n=2, the experiments were performed
in duplicate.
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5. DISCUSSION
In the present study GR signalling and the effect of IL-1b on glucocorticoid receptor function was
investigated in two different intestinal epithelial cell lines: in human colonic adenocarcinoma cell
line Caco-2, and rat intestinal cell line IEC-6.
Caco-2 was previously described to possess characteristics of normal small intestinal epithelium
(Jumarie, 1991); in vitro these cells express a similar array of cytokines as cultured primary epithe-
lial cells do (Jung, 1995).
For these reasons the cell line Caco-2 supposed be a well suited model system to investigate the
molecular mechanisms of glucocorticoid action within the intestinal epithelium in human.
IEC-6 is an adult rat small intestinal epithelial cell line. It is widely used model for normal crypt
cells in cultures. Rat cell lines (IEC-6, IEC-17, IEC-18) are frequently chosen instead of primary
crypt cells because the survival time of isolated primary cells is short (about three days) (Fonty,
1993; Quaroni, 1999).
The glucocorticoid receptor is an ubiquitously expressed transcription factor. Its distribution in the
colon is well characterised in rat model (Whorwood, 1993) and there is functional evidence for the
presence of the receptor in the human intestine since glucocorticoids increase sodium absorption in
normal and inflamed mucosa (Sandle, 1986).
In the present study we could show by Western blot analysis that glucocorticoid receptor protein is
expressed in both Caco-2 and IEC-6 cells.
We found that in Caco-2 cells the majority of glucocorticoid receptors reside in the nucleus, in case
of IEC-6 we detected GR mostly in the cytoplasm.
Immunostaining experiments confirmed these findings and, moreover, showed that dexamethasone
treatment resulted in GR translocation from the cytoplasm to the nucleus in IEC-6 but not in
Caco-2 cells. In the human cell line Dex had no effect on the pattern of glucocorticoid receptor
staining.
The latter result coincides with the observation of LaFond et al. that both liganded and nonliganded
forms of GR can be present only in the nucleus (LaFond, 1988). Raddatz et al came to the same
conclusion examining human hepatoma cell lines HepG2 and Hep3B (Raddatz, 1996), Brink et al.
observed nuclear localisation of the receptor both in presence and absence of hormone in rat hepa-
toma cells (Brink, 1992).
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Although the unliganded form of GR has been reported to be cytoplasmic, many data suggest that
its distribution is not unique, it can be cell line specific.
By transfection experiments both transactivation and transrepression by dexamethasone could be
analysed. Using a GR responsive element carrying reporter gene construct (pGRE-SEAP) the trans-
activation, by using a NF-kB responsive element carrying vector (pNF-kB-SEAP) the transrepres-
sion could be observed.
We found that in both cell lines treatment with dexamethasone resulted in a dose dependent tran-
scriptional activation of the reporter gene SEAP, and that this effect could be antagonised by the
specific GR antagonist RU 486. These findings demonstrate that glucocorticoid receptor is func-
tionally intact in Caco-2 and IEC-6 cells.
Numerous genes are known to be NF-kB regulated, e.g. IL-1b, IL-2, TNFa, IL-8, MCP-1.
It has been described that glucocorticoids can reduce the expression of some inflammatory media-
tors like TNFa or IL-8 in human peripheral blood mononuclear cells (Mukaida, 1989). Neurath et
al. found that inhibition of NF-kB activity using antisense oligonucleotide against NF-kB mRNA
improved experimental colitis in mice (Neurath, 1996), Rogler et al. reported that NF-kB is acti-
vated in intestinal epithelial cells and macrophages in biopsy speciments taken from IBD patients
(Rogler, 1998).
These experiences show that NF-kB is involved in the process of inflammatory bowel disease.
Moreover Su et al. have described a possible new, alternative treatment for patients suffering from
IBD. Their concept is that NF-kB can be inhibited by peroxisome proliferator-activated receptor-
gamma ligands as a new class of antiinflammatory substances (Su, 1999).
To monitor the transrepression of NF-kB by dexamethasone, the cell lines Caco-2 and IEC-6 were
transfected with NF-kB responsive element containing construct.
We found that IL-1b really caused increased reporter gene activity concentration dependently in
both cell lines but - surprisingly - Dex could reduce it only in the rat cells.
There are several reports describing altered GR expression and function in inflammatory processes
in vivo, like asthma (Spahn, 1995) or rheumatoid arthritis (DiBattista, 1993). Leung et al. observed
that cytokines may modulate the glucocorticoid sensitivity in glucocorticoid resistant asthma
(Leung, 1998).
Accordingly we hypothesised that IL-1b itself can have an influence on the glucocorticoid receptor
action. To answer this question we performed transfection experiments with pGRE-SEAP and ex-
amined the activating effect of Dex in presence of IL-1b.
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We found that treatment with IL-1b led to significant reduction in Dex induced GR mediated gene
transcription in case of both cell lines.
These results were confirmed by immunostaining experiments. By this method the shuttling of glu-
cocorticoid receptor could be examined only in IEC-6 cells since in case of Caco-2 we could not
detect any apparent change regarding receptor localization upon stimulation by glucocorticoids.
Anyway, in Dex-treated IEC-6 cells we found GR translocation from the cytoplasm to the nucleus,
but in presence of IL-1b the shuttling of GR could not be observed.
Simultaneous with our study Pariante et al. found that in the mouse fibroblast cell line, L929 the
proinflammatory cytokine, IL-1a reduced the glucocorticoid receptor translocation and function
and caused its up-regulation. (Pariante, 1999).
In contrast to Pariante’s observation, we did not find change in the receptor number in neither of our
cell lines.
Anyway, the effect of cytokine treatment on GR quantity is not clear, some researchers found
down-regulation, e.g. human recombinant IL-1 caused reduced receptor number in Reuber hepa-
toma cells (Hill, 1988), others observed up-regulation: Costas et al. described that TNFa increased
GR number in L-929 mouse fibroblasts  (Costas, 1996). This process seems to be cell line and cyto-
kine specific.
The inefficacy of dexamethasone on inhibition of TNFa mRNA expression in Caco-2 cells can be a
further evidence for the impaired glucocorticoid receptor action regarding transrepression. We
found that IL-1b can stimulate TNFa mRNA expression in both cell lines. We showed that dexa-
methasone could inhibit the IL-1b induced TNFa mRNA expression only in IEC-6 cells, in Caco-2
Dex was inefficient.
We found that IEC-6 cells contain significant more GR binding sites than Caco-2. The GR content
in Caco-2 is relatively low compared to other human epithelial cell lines e.g. Hela cells (Scheinman,
1995). Most certainly in Caco-2 cells the relative lack of glucocorticoid receptors play a role in the
inefficacy of dexamethasone to inhibit TNFa expression and NF-kB activation.
The glucocorticoid receptor quantity could be effectively increased by glucocorticoid receptor over-
expression. Thereafter we could present increased reporter gene activity after Dex treatment in
pGRE-SEAP transfected, GR overexpressing cells. This dramatically enhanced reporter gene activ-
ity could be observed only in Dex-treated cells, indicating that the transactivation is strictly hor-
mone dependent.
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An effective inhibition by dexamethasone was found regarding IL-1b induced, NF-kB mediated
SEAP activity in GR-overexpressing cells. Interestingly, unstimulated glucocorticoid receptor was
also capable of inhibiting NF-kB, suggesting, that the transrepressive effect of GR is not completely
hormone dependent.
Similar observations were described by Inoue et al. They found that in bovine arterial endothelial
cells Dex could not inhibit LPS stimulated prostaglandin E synthesis and LPS induced promoter
activity of the Cox-2 gene. Transfection with GR expression vector could restore the inhibitory ef-
fect of dexamethasone on the promoter activity of Cox-2 (Inoue, 1999).
These findings provide a cellular model for the process of glucocorticoid resistance. Our data sug-
gest that IL-1b does not only counteract the inhibitory effect of dexamethasone on NF-kB activity,
but also represses the GR mediated transactivation and the translocation of the receptor in Caco-2
cells.
A further question was how IL-1b could impair the glucocorticoid receptor action. One possible
explanation may be a protein-protein interaction between GR and other transcription factors. A
cross-talk has been described between GR and NF-kB in Hela cells by Scheinman et al. (Sheinman,
1995) and in the monkey kidney cell line, COS-1 by McKay and Cidlowski (McKay, 1998).
Concerning Caco-2 we hypothesised that a physical interaction between these two transcription
factors can cause the impairment of the GR action: if a high amount of IL-1b stimulated NF-kB
molecules are active, many GRs can be trapped, and prevents glucocorticoid receptor from binding
glucocorticoid receptor responsive elements. The intracellularly available receptor content can be a
limiting factor for NF-kB inhibition.
Another possible interaction between NF-kB and GR was reported by Sheppard et al. They found
that the p65 component of NF-kB and the glucocorticoid receptor mutually repress each other’s
ability to activate transcription: the maximal activity of both these transcription factors depends on
availability of the coactivators CREB-binding protein and steroid receptor coactivator 1 (SRC-1).
The cross-talk between p65 and GR was supposed to be due to a nuclear competition for limiting
amounts of the same coactivators (Sheppard, 1998).
To answer the question if NF-kB is the candidate transcription factor, that blocks GR action we
examined the effect of dexamethasone on Caco-2 cells in which NF-kB pathway was blocked by
overexpression of a mutant form of IkB, that irreversibly blocks NF-kB.
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Although we could show that in fact NF-kB activity was blocked, we found that glucocorticoid re-
ceptor action could not be restored by this way in Caco-2.
This finding suggests that in Caco-2 cells NF-kB is not responsible for the negative effects of IL-1b
on GR mediated transactivation.
The signalling cascade of IL-1b involves numerous transcription factors, which can be candidate for
impairing glucocorticoid receptor action either by protein-protein interaction or competition for
cofactors.
The function of these transcription factors is modulated via activation of protein kinase cascades by
IL-1b. One of these cascades involves a NF-kB inducing kinase. The activation of this kinase leads
to phosphorilation of IkB, degradation of NF-kB/IkB complex and activation of NF-kB. The sig-
nalling cascade also involves three distinct mitogen-activated kinase cascades, which modulate a
number of other transcription factors. The activating transcription factor-2 (ATF-2) and c-Jun,
which is one of the components of activating protein 1 (AP-1) is activated by the c-Jun-N-terminal
or stress-activated protein kinase. This pathway is activated in all responsive cells in tissue in vivo.
Cyclic AMP response element binding protein (CREB) is also activated by MAP kinase. Further-
more,   IL-1b activates the transcription factor NF-IL6, which is one of the main factors for the
transcriptional activation of IL-6 and IL-8 genes (Stylianou, 1998; O‘Neill, 1995).
Although the interaction between most of these transcription factors and glucocorticoid receptor
action is unclear, protein-protein interaction has been described between GR and c-Jun (Yang-Yen,
1990). So that AP-1 may be involved in the inhibition of GR pathway. Experiments using other
dominant negative expression vectors or antisense oligos are required to answer this question in the
future.
Furthermore, it has been reported that cytokines may act on heat shock proteins, which are one of
the components of the glucocorticoid receptor complex. D’Souza et al. described that interleukin 1
induced heat shock protein expression in human oligodendrocytes (D’Souza, 1994). IL-1b -induced
overexpression of heat shock proteins may keep glucocorticoid receptor anchored in the cytoplasm
and inhibit its translocation.
The intracellular cAMP level is an important regulator of glucocorticoid responsiveness. Rangara-
jan et al. described that both adenyl cyclase and protein kinase A activators have been found to in-
fluence glucocorticoid receptor function (Rangarajan, 1992). PKA up-regulated GR expression and
enhanced the affinity of glucocorticoids to GR in F9 embryonal carcinoma cells. Dong et al. de-
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scribed that cAMP enlarged the amount of GR by increasing the stability of its mRNA in rat hepa-
toma cells. (Dong, 1989). However, regulating the glucocorticoid sensitivity of the cell, defective
cAMP-dependent protein kinase may be involved in the process of glucocorticoid resistance.
The 11b-hydroxysteroid dehydrogenase (OHSD) is another important factor in the regulation of
glucocorticoid efficacy. This enzyme protects the non-selective mineralocorticoid receptor from
occupation by glucocorticoids by converting the active cortisone to inactive 11-
dehydrocorticosterone and maintains a normal in vivo specificity of mineralocorticoids for their
receptor. (Edwards, 1988; Funder, 1988). The enzyme was found to localize in the distal nephron,
where mineralocorticoids stimulate the transepithelial sodium transport (Stanton, 1986) and signifi-
cant levels of OHSD have been reported in the human rectum (Burton, 1983). Moreover, Whor-
wood et al. described its expression and activity in the rat distal colon, where adrenocortical steroids
also regulate the sodium transport  (Whorwood, 1993). Although there is clinical evidence only for
compromised OHSD-function (Stewart, 1989, Ulick, 1979), increased enzyme activity can modify
the efficacy of glucocorticoid drugs in IBD patients. Therefore the question if cytokines like IL-1b
may up-regulate the activity of OHSD should be investigated in the future.
In conclusion our data suggest that the proinflammatory cytokine IL-1b, which is produced during
intestinal inflammation, induces glucocorticoid resistance in the epithelial cell lines Caco-2 and
IEC-6. The mechanism of its inhibitory effect is unclear, NF-kB is not involved in the process in
Caco-2 cells on cellular level. The glucocorticoid receptor quantity of the cells is essential in the
efficacy of glucocorticoids. New, alternative treatment forms of the inflammatory bowel disease
may include gene therapy strategies utilizing glucocorticoid receptor overexpression.
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